UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): September 1, 2016

 

Enhance Skin Products Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   000-52755   84-1724410

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

50 West Liberty Street, Suite 880, Reno NV   80246
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (416) 306--2493

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

SECTION 1 - REGISTRANT’S BUSINESS AND OPERATIONS

 

ITEM 1.01 - ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

On September 1, 2016, the Company and Integumen Limited (“Integumen”) formerly Biosurface Limited entered into an agreement amending the Option Agreement entered into by the parties on July 7, 2016 as amended July 29, 2016, August 12, 2016 and August 24, 2016 (the “Option Amendment Agreement”). The Option Amendment Agreement extends the expiration date of the option in the Option Agreement from September 1, 2016 to September 8, 2016. All other terms of the Option Agreement remain unchanged.

 

The foregoing description of Option Amendment Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the foregoing document, which is filed as Exhibits 10.1 hereto, and which is incorporated herein by this reference.

 

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

10.1 Option Amendment Agreement

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Enhance Skin Products Inc.
     
  By: /s/ Donald Nicholson
    Donald Nicholson
    President/CEO, Principal Executive Officer

 

Dated: September 1, 2016